Biomarkers
| Product Code | GIA01690 |
| Publication Date | August 2011 |
| Publisher | Global Industry Analysts |
| Product Type | Report |
| Pages | 1305 |
| ISBN Number | not applicable |
Biomarkers
This report analyzes the worldwide markets for Biomarkers in US$ Million by the following Technologies and Services: Technologies - Emerging Biomarker Technologies (Imaging biomarkers, Proteomics, Transcriptomics, & Bioinformatics), Conventional Biomarker Technologies - (Immunodiagnostics, & Molecular Diagnostics), and Others; Services - Clinical Biomarker Services, Specimen Preparation, and Bioinformatics and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular). Key Therapeutic Areas also analyzed in the report include Oncology, Cardiology, CNS, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 204 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Agilent Technologies, Inc., Alexion Pharmaceuticals, Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMérieux, Bruker Corporation, Caprion Proteomics, Inc., Clarient Inc., Compugen, Ltd., Correlogic Systems, Inc., DiagnoCure, Inc., Epigenomics AG, GE Healthcare, Gene Logic, Genedata AG, Gen-Probe Inc., GlaxoSmithKline Plc, Hitachi Medical Corporation, Illumina, Inc., LabCorp., Life Technologies Corporation, Merck & Co. Inc., Metabolon, Inc., Myriad Genetics, Inc., Novartis International AG, Panacea Laboratories, Pfizer, Inc., Philips Healthcare, QIAGEN NV, Quest Diagnostic, Inc., Quest Diagnostics Company, Roche Diagnostics Corp., Rubicon Genomics, Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Contents
- 1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definition and Scope of Study
- Definitions
- Biomarker Technologies
- Emerging Biomarker Technologies
- Proteomics
- Transcriptomics
- Imaging biomarkers
- Bioinformatics
- Conventional Biomarker Technologies
- Molecular Diagnostics
- Immunodiagnostics
- Other Biomarker Technologies
- Metabolite and Enzyme Assays
- Reagents
- Biomarker Services
- Clinical Biomarker Services
- Biomarker Testing
- Assay Development and Production
- Antibody Development
- Specimen Preparation
- Bioinformatics and Others
- 2.INDUSTRY OVERVIEW
- Global Biomarkers Market Surges in the Backdrop of Widening Medical Scope and Applications
- Factors Engendering Positive Vibes
- Factors Engendering Positive Influence on the Biomarkers Market: A Summary
- Biomarkers: A Regional Perspective
- US Spearheads the Global Biomarkers Market
- US and Japan Take Lead on the Patent Front
- Table 1: Dominance of US in the Global Biomarker Patent Filings (includes corresponding Graph/Chart)
- Table 2: Leading Players in the Biomarkers Space by Number of Patent Filings (includes corresponding Graph/Chart)
- Table 3: Number of Biomarker Patents Published and Filed: 2003-2007 (includes corresponding Graph/Chart)
- Asia-Pacific: The Fastest Growing Biomarker Market
- Supportive Governments and Regulatory Bodies to Fuel Growth
- Increasing Collaborations Among Regulators and Companies Augur Well for Biomarkers
- Player Strategies: An Insight
- Table 4: Growing Number of Biomarker Deals (includes corresponding Graph/Chart)
- Table 5: Competitive Strategy Mix in the Global Oncology Biomarkers Market (includes corresponding Graph/Chart)
- Pharma and Biomarker Developer Tie-Ups to Raise Drug Development Productivity
- 3.MARKET OUTLOOK
- Biomarkers: Evolving Scope and Applications
- Technological Advancements - A Boon for Biomarker Discovery
- Evolving Role of Biomarkers in Drug Development
- Companion Biomarkers
- Biomarkers Play Invaluable Role in Oncology and Cardiovascular Disease Diagnosis
- Personalized Medicine- Revolutionizing the Medical Treatment
- Biomarker-Led Drug Discovery - A Profitable Investment
- Technological Trends
- Proteins Gain Upper Hand in Biomarkers
- Mass Spectrometry - A Promising Technology in Molecular Medicine
- Market Restraints
- Challenges in Biomarker Validation - A Major Growth Retardant
- The Road Ahead
- Biomarkers to Witness Significant Growth in Therapeutic and Diagnostic Arenas
- Efficiency Improvements Must for Realizing Cost-Effective Biomarker Testing
- 4.BIOMARKER TECHNOLOGIES AND SERVICES: AN OVERVIEW
- Biomarker - Definition & Introduction
- BIOMARKER TECHNOLOGIES
- EMERGING BIOMARKER TECHNOLOGIES
- Proteomics
- Growth Drivers and Market Trends
- Efficiency Gains in Drug Discovery Drive Growth in Proteomics
- Proteomics Witness Increased Focus on Targeted Approach
- Mass Spectrometry -Shifts in Focus to Proteomics Helps Biomarker Development
- Mass Spectrometry Expands Scope of Protein Biomarker Applications
- Transcriptomics
- Transcriptomics - Assisting in Identification of Biomarkers
- Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way
- Types of Imaging Biomarkers - An Overview
- Market Trends
- Molecular Imaging - Gaining Importance in Drug Discovery and Development
- Use of Molecular Imaging in Clinical Trials for Drug Development
- Bioinformatics
- CONVENTIONAL BIOMARKER TECHNOLOGIES
- Molecular Diagnostics
- Immunodiagnostics
- Market Trends
- Growth in Use of Molecular Diagnostics to Propel Biomarker Growth
- Demand for Novel Biomarkers Persists in Immunodiagnostics
- Immunoassays Plagued with Standardization Issues
- OTHER BIOMARKER TECHNOLOGIES
- Metabolite and Enzyme Assays
- Reagents
- Market Trends
- Microarrays Surge Biomarker Identification
- Metabolomics Gain Rapid Foothold in Drug Discovery
- BIOMARKER SERVICES
- Expanding Capabilities Drive Large-Scale Adoption
- Clinical Biomarker Services
- Biomarker Testing
- Assay Development and Production
- Antibody Development
- Specimen Preparation
- Bioinformatics and Other Biomarker Services
- Bioinformatics Gain Prominence
- miRNA Analysis
- Microarray Services Witness Increasing Investments
- 5.BIOMARKERS MARKET BY APPLICATION
- Role of Biomarkers in Drug Discovery and Development
- Role of Biomarkers in Clinical Research and Patient Management
- Major Benefits of Biomarkers in Clinical Development
- Major Benefits of Biomarkers in Medicine
- Multifarious Applications of Biomarkers
- New Applications Come to the Fore
- Application of Biomarkers in Drug Development
- Herceptin and Vilazodone -References for Success of Biomarker Based Approach
- Increasing Role of Biomarkers in Modern Drug R&D
- Translational Medicine Biomarkers Revolutionizing Drug Development Process
- Outsourcing - Opportunities Galore
- CROs in a Dilemma Over Investments in Biomarker Analysis Services
- Lower Productivity of Traditional Drug Discovery Approach Calls for New Methods
- Blockbuster Model Versus Personalized Medication Model
- Workflow Standardization - Key to Success of Biomarkers in Drug Development
- 6.BIOMARKERS BY THERAPEUTIC AREA
- Current & Future Analysis
- ONCOLOGY
- Factors Driving Oncology Biomarkers' Growth
- US Remains at the Forefront of Cancer Biomarker Patent Filings
- Table 6: Regional Split in the Global Cancer Biomarker Patent Filings: 2009 (includes corresponding Graph/Chart)
- Table 7: Leading Players in Cancer Biomarkers by Number of Patent Filings: 2004-2009
- Global Oncology Diagnostics and Drug Discovery Biomarkers Market
- Table 8: World Recent Past, Current and Future Analysis for Oncology Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 9: World 10-Year Perspective for Oncology Biomarkers Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 10: Global Cancer Biomarkers Diagnostics (Molecular) Market by Company (2009): Market Share Breakdown of Revenues for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others (includes corresponding Graph/Chart)
- Evolution of Oncology Biomarkers
- Available and Pipeline Biomarkers in Various Cancers
- Breast Cancer Dominates Cancer Biomarkers Pipeline
- Table 11: Global Cancer Biomarkers Pipeline by Indication (2010): Percentage Share Breakdown for Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and Others (includes corresponding Graph/Chart)
- Table 12: Global Oncology Biomarkers Market: Percentage Breakdown of Patent Filings by Oncology Area (2007)
- Breast Cancer Market Awaits New Specific Biomarkers
- Oncology Biomarker Diagnostic Techniques
- Table 13: Leading Cancer Biomarker Diagnostic Technologies (2009): Percentage Share of Value Sales for Gene-based Markers, Proteomics, DNA Microarrays, Immunological Markers and IHC Tests, and Others (includes corresponding Graph/Chart)
- Current Trends in Cancer Biomarkers
- Validation Techniques Take Center Stage
- Early-Stage Use of Biomarkers High in Oncology
- Proteomics Ahead of Genomic Biomarkers in Functionality
- Pharmacogenomics and IHC Tests Inch Ahead in Cancer Biomarker Diagnostics
- Faster Diagnosis Benefits DNA Microarray Technology
- Other Tests Lose Market Share
- Companion Biomarkers in Oncology
- CARDIOLOGY
- Market Trends
- Increasing Health Burden Drives Research Efforts
- Gene Expression Analysis Delivers Novel Therapeutic Approaches
- High-Performance Techniques Drive Biomarker Discovery in Cardiology
- Effective Phenotyping Takes Precedence for Successful Genotyping Studies
- Role of Linkage Analysis in Cardiovascular Biomarker Identification
- Biomarkers of ACS
- Biomarkers - A Promising Diagnostic Tool for ACS
- Biomarker Discovery in Cardiovascular Diseases to Undergo Significant Changes
- Major Cardiovascular Diagnostic Biomarkers - A Focus on Biomarkers for ACS
- Creatine Kinase-Myocardial Band
- Natriuretic Peptides
- Cardiac Troponin
- Myoglobin
- New Diagnostic Biomarkers for ACS on the Anvil
- Genomic Biomarkers for Detecting Cardiovascular Diseases
- Growing Demand for Stroke Biomarkers
- Rising Incidence of the Disease - A Major Driver for Stroke Biomarkers
- CENTRAL NERVOUS SYSTEM (CNS)
- Lower Commercial Availability Restricts Market Share
- Research Efforts Remain Confined to Specific Areas
- High Cost of Treatment Shadows Biomarkers' Short-Treatment Benefits
- Research Methodology in CNS Biomarkers
- Alliances - A Key Aspect to the Development of CNS Biomarkers
- Biomarkers in Select CNS Diseases
- Alzheimer's Disease
- Parkinson's Disease Biomarkers - Crucial for Neuroprotectants' Effectiveness
- Schizophrenia: An Unexploited Segment
- OTHER THERAPEUTIC AREAS
- Inflammatory and Autoimmune Disorders
- Biomarkers offer Efficient Diagnosis and Treatment
- Rheumatology
- 7.AN OVERVIEW OF SELECT BIOMARKERS
- HER2/neu/ ErbB2 Gene
- HER2 and its Association with Cancer
- Target Drugs for HER2
- Hepsin Biomarkers
- Early Prostate Cancer Antigen-2
- MMP-3
- ImmunoCyt™/uCyt+™
- AmpliChip CYP450 Test
- The OncoVue® Breast Cancer Risk Test
- Oncotype DX® Test
- Oncotype DX Colon Cancer Assay
- MammaPrint
- Theros CancerTYPE ID
- PgxPredict:CLOZAPINE- Test for Qualifying Patients to Use Clozapine
- The Pathwork Tissue of Origin Test
- PROGENSA PCA3 Assay
- Epi proColon® Early Detection Assay
- OVA1® Test
- Bcr-abl Fusion Protein
- HLA-B
- Mammostrat®
- Ipsogen MapQuant Dx™ Genomic Grade
- CA1-18 Enzyme Immunoassay (EIA)
- Anti-L523S Antibody
- 8.PRODUCT INTRODUCTIONS IN THE BIOMARKERS SPACE
- RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker Tests
- Avantra Introduces New BioChip Immunoassay Biomarker Workstation
- Clarient Introduces Mammostrat Test
- Biomagnetics Diagnostics Identifies Second Biomarker for Tuberculosis Assay
- Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay
- Crescendo Bioscience Launches New Multi Biomarker Blood Test
- Alere International Launches New Triage® NT-proBNP Test
- Agilent Technologies Launches New SureSelect Kinome Target Enrichment Kit
- Roche Diagnostics to Launch New STAT Immunoassays
- Gentel Biosciences Launches New Human Profiling Kits
- QIAGEN Introduces QIAsymphony RGQ System
- Almac Introduces Biomarkers for Biopharmaceutical Industry
- i-Path Introduces TMA Toolbox
- Abbott Introduces ARCHITECTPLUS Systems
- Affymetrix Introduces QuantiGene® ViewRNA Assayformats
- ARUP Laboratories Introduces New Test for Colorectal Caner Detection
- Warnex Launches Blood Testing Service for Colorectal Cancer in Canada
- Agilent Technologies Launches mAb-Glyco-Chip
- synlab Launches Septin9 Testing in Germany
- IDBS Introduces New Biomarker Discovery and Validation Solution
- Quest Diagnostics Introduces Blood Test for Detecting Colorectal Cancer
- Clarient Introduces Biomarker Panel for NSCLC Classification
- Institute of Microelectronics and Agency for Science, Technology and Research Launch Rapid Cardiac Biomarker Test
- Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment
- Thermo Fisher Introduces New Copeptin Assay
- Psynova Neurotech and RBM Identify New Biomarkers for Schizophrenia
- Genedata Unveils Genedata Expressionist® 5.3
- Arrayit Introduces Biomarker Discovery Service
- Invitrogen Introduces Biomarker Tool for Kidney Function Research
- Abbott Introduces ARCHITECT® c4000®
- Epigenomics Rolls Out Epi proColon Range in Europe
- Genedata Introduces Expressionist 5.2 for Identifying MS-based Biomarker
- VisEn Unveils FAST - A Novel Imaging Platform
- Millipore and CXR Biosciences Unveils ToxReporter™
- Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile
- MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System
- Genetic Biomarkers for Chronic Kidney Disease
- Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer
- Satoris Introduces three Novel Blood Tests
- GE Healthcare Launches Discovery™ MR450
- GE Healthcare in Partnership with Varian Launches Discovery MR901 (US)
- Applied Biosystems and MDS Analytical Launches Novel New Mass Spectrometry Tools
- Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker Panel
- Thomson Reuters Introduces BIOMARKERcenter
- Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker Array Kit
- BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test
- mtm laboratories Introduces Cervatec™ Assay
- Decision Biomarkers Introduces AVANTRA Biomarker Workstation
- Aureon Introduces Prostate Px® to Predict Progression and Recurrence of Prostrate cancer
- VisEn Introduces a Novel Imaging Agent
- 9.BIOMARKERS M&A ACTIVITY
- QIAGEN to Take Over Stake in Alacris Theranostics
- Transgenomic Acquires Certain Businesses of Clinical Data
- Caliper Life Sciences Acquires Cambridge Research & Instrumentation
- Biosystems International and MicroBioChips Merge
- Axela Takes Over Xceed Molecular
- Accelrys Merges with Symyx Technologies
- Caprion Proteomics Acquires PPD's Biomarker Division
- QIAGEN Takes Over SABiosciences
- Thermo Fisher Scientific Takes Over Brahms
- QIAGEN Takes Over DxS
- ICON Takes Over Veeda Laboratories
- ID Business Solutions Takes Over InforSense
- Clinical Data Acquires Avalon Pharmaceuticals
- Genetix Takes Over SlidePath
- Oxford Gene Technology Takes Over Sense Proteomic
- Tethys Bioscience Takes Over Lipomics Technologies
- QPS LLC Acquires Bio-Kinetic Clinical Applications
- AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service
- 10.COLLABORATIONS AND AGREEMENTS
- Proteome Sciences Bags Contract from Eisai
- MDxHealth to Ink Partnership Agreement with Pfizer, Cancer Research Technology and Newcastle University
- Takeda and Zinfandel Enter into License Agreement for AD Biomarker
- Pacific Biomarkers Forges Research Deals with Two Multinational Firms
- SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker
- Epigenomics Enters into Collaboration with QIAGEN to Develop Colorectal Cancer Blood Tests
- Vermillion Inks Agreement with Quest to Launch OVA1® in India
- DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD
- Prometheus Signs Agreement with The Regents of the University of California
- Aushon BioSystems Enters into Partnership with LightArray Biotech
- GE Healthcare Collaborates with Johnson & Johnson
- ICON Enters into Strategic Alliance with Proteome Sciences
- Epigenomics Inks Distribution Agreement with DATEKS
- Epigenomics Inks Distribution Agreement with Pronto Diagnostics
- Thermo Fisher Collaborates with Proteome Sciences
- Diaceutics Teams Up with London Genetics to Develop Software Decision Tools
- OncoMethylome Enters Into Agreement with GlaxoSmithKline Biologicals
- SureGene Enters into Research Collaboration with Medco Research Institute
- Ariadne Inks Agreement with Roswell Park Cancer Institute and Cellecta
- SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers
- Roche Acquires Co-exclusive License from QIAGEN
- Metabolon Collaborates with Colgate-Palmolive for Periodontal Disease Biomarkers Identification
- Toscana Biomarkers and Regione Toscana Enter into Grant Agreement
- ACC and Roche Diagnostics Initiate Collaboration
- Epigenomics Inks Distribution Agreement with DPC LEBANON
- Duke Enters into Joint Venture with LabCorp for Biomarker Commercialization
- HDC and SPM Enter Into Agreement with Quest Diagnostics
- oscana Biomarkers Collaborates with QuantiScientifics
- Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical Diagnostics
- Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences
- PAREXEL Enters into Partnership with Proteome Sciences
- Biocartis Inks Agreement with Royal Philips Electronics
- QIAGEN Signs Agreement with Wuxi AppTec
- SDIX Enters into Collaboration with Fred Hutchinson Cancer Research Center
- Siemens Teams UP with EDPL to Institute Cyclotron Facility in India
- ALS TDI Concluded First Phase of Collaboration with Applied Proteomics
- Psynova Neurotech Teams Up with Roche for Schizophrenia Treatment Development
- Minerva Biotechnologies Licenses Exclusive Marketing Rights to Clarient
- Rules-Based Medicine Signs Biomarker-Driven Agreement with Covance
- BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker
- Epigenomics and ARUP Ink Non-Exclusive Agreement
- Biosystems International Signs Licensing Agreement with Lohocla Research
- Axela Signs Agreements with Micromedics and Proteome Sciences
- Moffitt Cancer Center and Frantz BioMarkers Enter into Licensing Agreement
- Fujirebio Diagnostics Signs Agreement with BD for Oncology Diagnostic Assays
- Quest Diagnostics Bags Prostrate Cancer Test License from Epigenomics
- Genedata Extends Collaboration Agreement with Roche
- BioTheranostics Inks Commercialization Agreement with Lab 21 for THEROS CancerTYPE ID
- Researchers Utilizes AB Sciex Qtrap 5500 System to Detect Biomarkers
- Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer Test
- Caprion and Applied Bioystems Partners to Accelerate Validation and Verification of Protein Biomarker
- Sysmex Inks Research Partnership Deal with Epigenomics
- Pharsight Inks Agreement with InforSense
- AstraZeneca and Washington University Team Up to Develop Novel Methods for Alzheimer's Disease Diagnosis and Treatment
- 11.OTHER CORPORATE INITIATIVES IN BIOMARKERS SPACE
- Genedata Installs Genedata Expressionist® Refiner MS at Victoria DPI
- Genedata Deploys Genedata Expressionist® at Hospital for Sick Children
- Covance Establishes New Unit for Discovery and Translation Services
- The University of Liège Spins-off Targetome Business
- PMDA Accepts Biomarker Panel of Critical Path's
- Clarient Obtains UK Patents for the TLE3 Biomarker
- Agilent Supplies Mass Spectrometry Devices to Stemina Biomarker Discovery
- Pacific Biomarkers to Launch New Logo, Marketing and Branding Initiatives
- SMA Foundation Completes Biomarker Study
- Genedata Offers Genedata Expressionist® to RIKEN
- Chronix Biomedical Strengthens Biomarker Development Capabilities
- Aureon Changes Name of Colorectal Cancer Prognostic Test
- Satoris Gains Global Distribution Rights to RBM's DiscoveryMAP™ Panel
- Teva Pharmaceutical Industries to Use Biomarkers of Compugen
- Genedata Provides Genedata Expressionist® System to Asubio Pharma
- InforSense Aids Biomarker Discovery Process by Celera
- Xennex Provides Satoris with Access to GeneCards®
- IME Developed Silicon-Based Testing System for Cardiac Biomarkers
- 12.FOCUS ON SELECT GLOBAL PLAYERS
- Abbott Laboratories (US)
- Affymetrix, Inc. (US)
- Agilent Technologies, Inc. (US)
- Alexion Pharmaceuticals, Inc. (USA)
- Beckman Coulter, Inc. (US)
- Becton, Dickinson and Company (US)
- Bio-Rad Laboratories, Inc. (US)
- BioMérieux (France)
- Bruker Corporation (US)
- Caprion Proteomics, Inc. (Canada)
- Clarient Inc. (US)
- Compugen, Ltd. (Israel)
- Correlogic Systems, Inc. (US)
- DiagnoCure, Inc. (Canada)
- Epigenomics AG (Germany)
- GE Healthcare (UK)
- Gene Logic (US)
- Genedata AG (Switzerland)
- Gen-Probe Inc. (US)
- GlaxoSmithKline Plc. (UK)
- Hitachi Medical Corporation (Japan)
- Illumina, Inc. (US)
- LabCorp. (US)
- Life Technologies Corporation (US)
- Merck & Co., Inc. (US)
- Metabolon, Inc. (US)
- Myriad Genetics, Inc. (US)
- Novartis International AG (Switzerland)
- Panacea Laboratories (US)
- Pfizer, Inc. (US)
- Philips Healthcare (Netherlands)
- QIAGEN NV (The Netherlands)
- Quest Diagnostic, Inc. (US)
- Roche Diagnostics Corp. (US)
- Rubicon Genomics, Inc. (US)
- Rules-Based Medicine, Inc. (US)
- Siemens Healthcare Diagnostics, Inc. (US)
- 13.GLOBAL MARKET PERSPECTIVE
- Table 14: World Recent Past, Current and Future Analysis for Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 15: World 10-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 16: World Recent Past, Current and Future Analysis for Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 17: World 10-Year Perspective for Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 18: World Recent Past, Current and Future Analysis for Biomarker Technologies by Segment - Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 19: World 10-Year Perspective for Biomarker Technologies by Segment - Percentage Breakdown of Dollar Sales for Emerging Biomarker Technologies, Conventional Biomarker Technologies, and Other Biomarker Technologies Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 20: World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 21: World 10-Year Perspective for Emerging Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 22: World Recent Past, Current and Future Analysis for Emerging Biomarker Technologies by Segment - Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 23: World 10-Year Perspective for Emerging Biomarker Technologies by Segment - Percentage Breakdown of Dollar Sales for Imaging biomarkers, Proteomics, Transcriptomics, and Bioinformatics Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 24: World Recent Past, Current and Future Analysis for Imaging Biomarkers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 25: World 10-Year Perspective for Imaging Biomarkers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 26: World Recent Past, Current and Future Analysis for Proteomics in Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 27: World 10-Year Perspective for Proteomics in Biomarker Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 28: World Recent Past, Current and Future Analysis for Transcriptomics in Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 29: World 10-Year Perspective for Transcriptomics in Biomarkers Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 30: World Recent Past, Current and Future Analysis for Bioinformatics in Biomarkers Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 31: World 10-Year Perspective for Bioinformatics in Biomarkers Market by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 32: World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 33: World 10-Year Perspective for Conventional Biomarker Technologies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 34: World Recent Past, Current and Future Analysis for Conventional Biomarker Technologies by Segment - Immunodiagnostics and Molecular Diagnostics Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 35: World 10-Year Perspective for Conventional Biomarker Technologies by Segment - Percentage Breakdown of Dollar Sales for Immunodiagnostics and Molecular Diagnostics Markets for Years 2008, 2011, and 2017 (includes corresponding Graph/Chart)
- Table 36: World Recent Past, Current and Future Analysis for Immunodiagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 37: World 10-Year Perspective for Immunodiagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 38: World Recent Past, Current and Future Analysis for Molecular Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 39: World 10-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 40: World Recent Past, Current and Future Analysis for Other Biomarker Technologies by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 41: World 10-Year Perspective for Other Biomarker Technologie by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 42: World Recent Past, Current and Future Analysis for Biomarker Services by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 43: World 10-Year Perspective for Biomarker Services by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 44: World Recent Past, Current and Future Analysis for Biomarker Services by Segment- Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 45: World 10-Year Perspective for Biomarker Services by Segment - Percentage Breakdown of Dollar Sales for Clinical Biomarker Services, Specimen Preparation, and Other Biomarker Services Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 46: World Recent Past, Current and Future Analysis for Clinical Biomarker Services by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 47: World 10-Year Perspective for Clinical Biomarker Services by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 48: World Recent Past, Current and Future Analysis for Specimen Preparation by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 49: World 10-Year Perspective for Specimen Preparation by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 50: World Recent Past, Current and Future Analysis for Other Biomarker Services by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 51: World 10-Year Perspective for Other Biomarker Services by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 52: World Recent Past, Current and Future Analysis for Biomarkers by Application - Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 53: World 10-Year Perspective for Biomarkers by Application - Percentage Breakdown of Dollar Sales for Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular) Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 54: World Recent Past, Current and Future Analysis for Biomarkers by Therapeutic Area - Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 55: World 10-Year Perspective for Biomarkers by Therapeutic Area - Percentage Breakdown of Dollar Sales for Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 14.THE UNITED STATES
- A. Market Analysis
- Current & Future Analysis
- Companies Wake Up to the Growing Need for Effective Biomarkers
- Biomarker Regulations in the US
- Product Launches
- Strategic Corporate Developments
- Focus on Select Major Players
- B. Market Analytics
- Table 56: The US Recent Past, Current and Future Analysis for Biomarkers by Segment-Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 57: The US 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 15.CANADA
- A. Market Analysis
- Current & Future Analysis
- Product Launch
- Strategic Corporate Developments
- Focus on Select Major Players
- B. Market Analytics
- Table 58: Canadian Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 59: Canadian 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 16.JAPAN
- A. Market Analysis
- Current & Future Analysis
- Strategic Corporate Developments
- Hitachi Medical Corporation - A Key Player
- B. Market Analytics
- Table 60: Japanese Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 61: Japanese 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 17.EUROPE
- A. Market Analysis
- Current & Future Analysis
- Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D
- Biomarker Regulations in Europe
- EMEA's Experience in Pharmacogenetic Drugs - Still Nascent
- Uncertain Laws Discourage VC Funding in Europe
- Uncertainty Continues Among Regulators over Biomarker Validation Levels
- B. Market Analytics
- Table 62: European Recent Past, Current and Future Analysis for Biomarkers by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 63: European 10-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Table 64: European Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 65: European 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 17a.FRANCE
- A. Market Analysis
- Current & Future Analysis
- Strategic Corporate Development
- BioMérieux (France) - A Key Player
- B. Market Analytics
- Table 66: French Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 67: French 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 17b.GERMANY
- A. Market Analysis
- Current & Future Analysis
- Product Launches
- Strategic Corporate Development
- Epigenomics AG - A Key Player
- B. Market Analytics
- Table 68: German Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 69: German 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 17c.ITALY
- A. Market Analysis
- Current & Future Analysis
- Strategic Corporate Developments
- B. Market Analytics
- Table 70: Italian Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 71: Italian 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 17d.THE UNITED KINGDOM
- A. Market Analysis
- Current & Future Analysis
- Product Launches
- Strategic Corporate Developments
- Focus on Select Major Players
- B. Market Analytics
- Table 72: The UK Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 73: The UK 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 17e.REST OF EUROPE
- A. Market Analysis
- Current & Future Analysis
- Product Launches
- Strategic Corporate Developments
- Focus on Select Major Players
- B. Market Analytics
- Table 74: Rest of European Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 75: Rest of European 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 18.ASIA-PACIFIC
- A. Market Analysis
- Current & Future Analysis
- Product Launches
- Strategic Corporate Developments
- B. Market Analytics
- Table 76: Asia-Pacific Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 77: Asia-Pacific 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Servicesz [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- 19.REST OF WORLD
- A. Market Analysis
- Strategic Corporate Development
- Compugen Ltd. (Israel)- A Key Player
- B. Market Analytics
- Table 78: Rest of World Recent Past, Current and Future Analysis for Biomarkers by Segment- Biomarker Technologies [Emerging Biomarker Technologies Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2008 through 2017 (includes corresponding Graph/Chart)
- Table 79: Rest of World 10-Year Perspective for Biomarkers by Segment - Percentage Breakdown of Dollar Sales for Biomarker Technologies [Emerging Biomarker Technologies (Imaging Biomarkers, Proteomics, Transcriptomics and Bioinformatics), Conventional Biomarker Technologies (Immunodiagnostics and Molecular Diagnostics) and Others] and Biomarker Services [Clinical Biomarker Services, Specimen Preparation and Others] Markets for Years 2008, 2011 and 2017 (includes corresponding Graph/Chart)
- Total Companies Profiled: 204 (including Divisions/Subsidiaries - 210)
- Region/CountryPlayers
- The United States
- Canada
- Japan
- Europe
- France
- Germany
- The United Kingdom
- Italy
- Rest of Europe
- Asia-Pacific (Excluding Japan)
- Middle-East